

EURION cluster presentations at the ED Forum

17 December 2020 – ED Forum

Andreas Kortenkamp

Majorie van Duursen

Juliette Legler



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu

Three EURION cluster presentations

Thyroid hormone system – Andreas Kortenkamp

Female reproductive health – Majorie van Duursen

Metabolic disruption – Juliette Legler



Common questions

What are the testing gaps and challenges today?

How does EURION address these?

What can be done immediately to improve the situation?





Gaps in test methods for identifying thyroid hormone system disruption

17 December 2020 – ED Forum

Andreas Kortenkamp




These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu

Low thyroid hormones in pregnancy = low IQ




3839 mother-child pairs

Korevaar et al. 2016, Lancet Diabetes Endocrinology




Sites of Interference for Thyroid Disrupting Chemicals



Gilbert, ME et al. 2020, Endocrinology 161, 1-17



Thyroid hormones are essential for three steps of brain development




Gilbert, ME et al. 2020, Endocrinology 161, 1-17



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu



Thyroid
relevant tests
in core data
sets to be
submitted for
placing
products on
the EU market

Thyroid hormone serum levels

Thyroid histopathology

- Regulation 283/2013 for Plant Protection Products
- Annex II of Biocidal Products Regulation 528/2012
- Regulation 444/2008 for tests pursuant to REACH chemicals

No in vitro tests

No tests for down-stream effects on the brain

Why thyroid hormone serum levels?


Assumption:

Diminished serum thyroid hormones = disrupted thyroid hormone action



Complex regulation of thyroid hormone action in target cells

Changes in serum thyroid hormone levels do not always translate into disrupted thyroid hormone action in tissues



Severe defects in thyroid hormone action, but small changes in serum thyroid hormones

Mutated **Thyroid Hormone Receptor Alpha** = no response to hormone

- **Neurodevelopmental deficits, skeletal abnormalities**
- Low to normal T4, normal TSH

Measurements of serum thyroid hormone would not detect this disorder!




Mutated thyroid hormone transporter MCT 8 – **Allan-Herndon-Dudley syndrome**


The brain cannot take up thyroid
hormones



Mutated thyroid hormone transporter MCT 8 – Allan-Herndon-Dudley syndrome



Groeneweg et al.
2020 Lancet
Diabetes
Endocrinology



The dilemma

Changes in thyroid hormone levels alone cannot detect risks to neurodevelopment

But:

We have nothing else!




Current consensus

In the absence of definitive biomarkers of altered neurodevelopment, thyroid hormone changes are appropriate **starting points** for risk assessment.

SOT 2017





SCREENED
SCREENING FOR ENDOCRINE DISRUPTORS



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu

How EURION cluster projects approach the challenges


- Development of ***in vitro assays***, including 3D models
- Development of **testing strategies** based on Adverse Outcome Pathway networks and read-across between vertebrate classes
- Development of **down-stream markers** of disrupted brain development



Misplaced neurons in the white matter

Control

Propylthiouracil, 2.5 mg/kg/d



a

b

Ramhoj et al. DTU



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu



European Cluster to
Improve Identification
of Endocrine Disruptors

Thank you!

CONTACT US:

EURION Coordination April 2020 - July 2021

Joëlle Rüegg

ENDpoiNTs

joelle.ruegg@ebc.uu.se

Henrik Holbech

ERGO

hol@biology.sdu.dk

Communication & Press

Avril Hanbidge

ERGO

avril@aquatt.ie



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825161 (ATHENA), No. 825762 (EDCMET), No. 825759 (ENDpoiNTs), No. 825753 (ERGO), No. 825100 (FREIA), No. 825489 (GOLIATH), No. 825745 (SCREENED), No. 825712 (OBERON). This output reflects only the author's view and the European Union cannot be held responsible for any use that may be made of the information contained therein.

@EurionCluster

www.eurion-cluster.eu